Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2020

View Archived Issues

Circulating miR-638 and miR-521: potential screening biomarkers for cervical squamous cell carcinoma

Acid test for therapeutic peptides

Mersana begins phase I study of XMT-1592 in NSCLC and ovarian cancer

Interim phase I data presented for mRNA-1273 coronavirus vaccine

Cellect's ApoGraft to be studied for treatment of COVID-19-related pulmonary diseases

Namodenoson reduces liver fat and fibrosis in phase II NAFLD study

FDA clears IND application for phase II study of merimepodib in advanced COVID-19

LATS2 and KIBRA are prognostic markers in patients with ccRCC

Intermediary results presented for VLP COVID-19 vaccine in mice

Heron Therapeutics initiates phase Ib/II study of HTX-034 for postoperative pain

Human L-opsin gene therapy shows potential for treating blue cone monochromacy

Incyte presents novel PI3K-gamma inhibitors

Janssen discovers novel potent EP inhibitors

ELX-01 shows functional activity in a model of nonsense mutation-related IRD

Metacrine patents new AOC3 inhibitors

Arrien Pharmaceuticals synthesizes MELK and/or FLT3 inhibitors

Bristol-Myers Squibb presents new Toll-like receptor antagonists

New adjuvant reverses MDR in Gram-negatives

New ATR kinase inhibitors identified by Repare Therapeutics

Maxinovel Pharmaceuticals patents PD-1/PD-L1 interaction inhibitors

FDA approves Tecentriq for first-line metastatic NSCLC with high PD-L1 expression

Sorrento's STI-1499 demonstrates 100% inhibition of SARS-CoV-2 virus infection in vivo

European Commission grants conditional approval for Zolgensma for SMA

Phase IIb study of Liproca Depot in prostate cancer meets endpoints

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...